Harmony Biosciences Holdings (HRMY) Net Cash Flow (2019 - 2026)

Harmony Biosciences Holdings has disclosed Net Cash Flow across 8 years of filings, most recently posting -$163.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$163.1 million, down 553.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.4 million (down 35.65% YoY), and the FY2025 annual result was $299.5 million, up 111.9% from the prior year.
• Net Cash Flow came in at -$163.1 million for Q1 2026 at Harmony Biosciences Holdings, down from $105.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $105.5 million in Q4 2025 to a low of -$163.1 million in Q1 2026.
• The 5-year median for Net Cash Flow is $24.8 million (2022), against an average of $20.9 million.
• Across the five-year window, Net Cash Flow surged 874.83% in 2024 and sank 553.1% in 2026, its largest moves.
• Harmony Biosciences Holdings' Net Cash Flow stood at -$17.6 million in 2022, then climbed by 26.4% to -$12.9 million in 2023, then jumped by 607.89% to $65.6 million in 2024, then soared by 60.74% to $105.5 million in 2025, then slumped by 254.6% to -$163.1 million in 2026.
• The last three Net Cash Flow figures came in at -$163.1 million (Q1 2026), $105.5 million (Q4 2025), and $100.9 million (Q3 2025), per Business Quant data.